Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $3.7 million.

  • Niagen Bioscience's Free Cash Flow rose 619.57% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year increase of 42088.67%. This contributed to the annual value of $11.9 million for FY2024, which is 7141.63% up from last year.
  • Per Niagen Bioscience's latest filing, its Free Cash Flow stood at $3.7 million for Q3 2025, which was up 619.57% from $1.1 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Free Cash Flow high stood at $8.5 million for Q4 2024, and its period low was -$8.2 million during Q2 2021.
  • Its 5-year average for Free Cash Flow is -$445000.0, with a median of $254000.0 in 2024.
  • As far as peak fluctuations go, Niagen Bioscience's Free Cash Flow tumbled by 188634.54% in 2021, and later surged by 299763.78% in 2025.
  • Over the past 5 years, Niagen Bioscience's Free Cash Flow (Quarter) stood at -$4.9 million in 2021, then skyrocketed by 89.89% to -$500000.0 in 2022, then surged by 225.6% to $628000.0 in 2023, then surged by 1255.73% to $8.5 million in 2024, then plummeted by 56.92% to $3.7 million in 2025.
  • Its Free Cash Flow was $3.7 million in Q3 2025, compared to $1.1 million in Q2 2025 and $7.9 million in Q1 2025.